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DOI 10.1016/j.stem.2007.12.001Retroviral transduction of the four tran-
scription factors Oct4, Sox2, Klf4, and
c-Myc has been shown to initiate a re-
programming process that results in the
transformation of mouse fibroblasts into
embryonic stem (ES)-like cells designated
as induced pluripotent stem (iPS) cells
(Maherali et al., 2007; Meissner et al.,
2007; Okita et al., 2007; Takahashi and
Yamanaka, 2006; Wernig et al., 2007).
The promise of somatic reprogramming
is the possibility to generate pluripotent
stem cells that are patient specific and
can be used as a unique source for autol-
ogous cell types for transplantation ther-
apy (Jaenisch, 2004; Yamanaka, 2007).
Many iPS cell-derived animals develop tu-
mors due to the reactivation of the c-Myc
virus (Okita et al., 2007), and this repre-
sents a major safety concern if we want
to translate this approach to humans. It
is thus of great importance to achieve re-
programmingwithout this particular onco-
gene in the future. Here we show that
fibroblasts can be reprogrammed to a plu-
ripotent state by Oct4, Sox2, and Klf4 in
the absence of c-Myc.
Based on our observation that the four-
factor-induced reprogramming is a slow
and gradual process and occurs also in
the absence of drug selection for reactiva-
tion of a pluripotency gene (Meissner
et al., 2007; Wernig et al., 2007), we rea-
soned that three factors might be able to
initiate a slower reprogramming process
that could be sufficient to fully reprogram
fibroblasts after a longer time period. To
test this possibility, we infected mouse
embryonic fibroblasts (MEFs) from Oct4-
neo and Nanog-neo mice with either all
four retroviruses or with Oct4, Sox2, and
Klf4 retroviruses only. When neomycin
was added at day 6 after infection, only
cells infected with all four factors devel-
oped resistant colonies, and no cells sur-
vived when infected with the three factors
alone (Figure 1A). To evaluate whether
reprogramming might be delayed without10 Cell Stem Cell 2, January 2008 ª2008 Elsc-Myc, we repeated the experiment and
carefully monitored the morphological
changes of the three- and four-factor-in-
fected cell populations over time in the
absence of neomycin. Although the four-
factor-infected cells began to generate
small colonies as early as on day 6, the
first morphologically discernable colonies
in the three-factor-infected cells were de-
tected at around day 21 after infection
(Figure 1A). About 4 weeks after infection,
none of these colonies displayed an iPS
cell phenotype yet, but they resembled
four-factor colonies found at much earlier
time points (Figure 1B, upper panels, see
also Meissner et al., 2007). When neomy-
cin was added to the plates at day 28,
some colonies survived the drug selec-
tion, indicating that the endogenous
Nanog and Oct4 genes had been reacti-
vated. However, in comparison to the
four-factor-infected cells, the number of
neomycin-resistant colonies was greatly
reduced (Figure 1A). To explore the timing
of the three-factor-induced reprogram-
ming on a clonal level, we picked all pri-
mary colonies that had formed in the
absence of neomycin at day 27 after in-
fection. From 100,000 infected cells, six
such colonies arose in Oct4-neo MEFs
(O1–6) and 12 in Nanog-neo MEFs (N1–
12). The picked cells were dissociated
and plated on a feeder layer of g-irradi-
ated MEFs in the absence of neomycin.
Most clones continued to divide but re-
sembled proliferating fibroblasts (such
as clone 3F-N1 on day 39 shown in
Figure 1B). iPS cell-like colonies ap-
peared at some point during our observa-
tion period in only four of the clones (for
example, clone 3F-N2 on day 39 in
Figure 1B, lower panels). All plates with
clones were passaged on feeders, and
the cells were morphologically monitored.
At each passage, half of the cells were
plated without and the other half with neo-
mycin to identify reprogrammed cells. The
majority of the clones retained their fibro-evier Inc.blast-like morphology and never became
neomycin resistant even after up to five
passages and as late as 68 days after in-
fection (see Figure S1 available online).
The cells only became neomycin resistant
in the subsequent passage when iPS cell-
like colonies had appeared (black line in
Figure 1 and green asterisk in Figure S1).
Two of the clones generated iPS cell-like
colonies in their first passage after picking
(clones N2 and N3 on days 29 and 43).
Two other clones remained fibroblast-
like and neo sensitive in their first passage
and developed neo-resistant iPS cell-like
colonies only after another passage
(clones O1 and N12 on days 33 and 63).
As shown in Figure 1C, the timing of re-
programming, as defined by development
of neomycin-resistant iPS cell-like colo-
nies, was variable between individual
clones ranging from 30 to about 70 days
after infection. From these data, we con-
clude that the reprogramming process
was substantially delayed (30 versus
6 days after infection), and the overall
efficiency was reduced by one to two or-
ders of magnitude when c-Myc was not
transduced.
We next addressed the question of
whether these Oct4- and Nanog-resistant
clones were in fact equivalent to four-fac-
tor iPS cells or regular ES cells. Immuno-
fluorescence analysis revealed that both
Oct4- and Nanog-neo clones homoge-
nously expressed Nanog protein and the
ES cell epitope SSEA1 (Figures 2A and
2B). Moreover, we detected a strong alka-
line phosphatase activity in all three-fac-
tor iPS cell clones analyzed (Figure 2C).
Like the previously described four-factor
iPS cells, the three-factor iPS cells could
be maintained in regular ES cell condi-
tions without neomycin. Thus, the repro-
grammed state was stable and not de-
pendant upon the selective pressure to
express Nanog or Oct4. To test whether
the cells were pluripotent, 5 3 106 cells
were injected subcutaneously into SCID
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mors 4 weeks after injection revealed the
presence of various cell types represent-
ing all three germ layers (Figures 2D and
2E). Moreover, when injected into diploid
blastocysts, two of the four lines (the lines
3F-N2 and 3F-O1) readily produced viable
high-grade chimeric newborn and adult
mice (Figures 2F and 2G). Thus, mouse fi-
broblasts reprogrammed by transduction
of Oct4, Sox2, and Klf4 alone aremorpho-
logically and functionally indistinguish-
able from four-factor-iPS cells.
The results of this study have two im-
portant implications. (1) The three factors
Oct4, Sox-2, and Klf4 are sufficient to
Figure 1. Timing and Efficiency of Direct
Reprogramming without c-Myc
(A) Comparison of three-factor (3F) and four-factor
(4F) reprogramming. Indicated are the days when
the first colony formation was observed (colonies)
and the number of neomycin-resistant colonies
when selected 6 days (neo d6) or 28 days after in-
fection (neo d28).
(B) Shown are two primary colonies of Nanog-neo
MEFs at day 27 after infection with the three fac-
tors before picking (top row, 3F-N1 and 3F-N2).
When infected with the three factors and c-Myc,
similar colonies developed but at a much earlier
time point (top right panel, 4F 11 days after in-
fection). After picking and plating into separate
dishes, most clones resemble proliferating fibro-
blasts like clone 3F-N1 at passage 2 after picking
39 days after infection (lower left panel). In some
clones, a fraction of the cells began to generate
iPS cell-like colonies, such as clone 3F-N2 on
day 39 (middle lower panel). These colonies be-
came neomycin resistant (lower right panel shows
the sister dish of clone 3F-N2 in neomycin media;
note that the observed neomycin-resistant fibro-
blasts are irradiated feeder cells). Scale bar upper
panels, 100 mm; scale bar lower panels, 200 mm.
(C) Summary of all six Oct4-neo (3F-O1 to 6) and
all 12 Nanog-neo colonies (3F-N1 to 12) that
were picked and expanded. The dashed gray lines
denote a fibroblast-likemorphology; black lines in-
dicate the appearance of iPS cell colonies that
became neomycin resistant in the subsequent
passage.
induce pluripotency in mouse fibroblasts.
But the three-factor reprogramming pro-
cess is substantially delayed compared
to cells transduced also with c-Myc. It ap-
pears that the autoregulatory loop of the
three endogenous pluripotency genes
Oct4, Nanog, and Sox2 that maintains
pluripotency in ES cells (Boyer et al.,
2005) is more efficiently and more rapidly
established when c-Myc is added to the
three other reprogramming factors. It is
conceivable that one major function of
c-Myc is to enhance proliferation, thereby
accelerating the reprogramming process.
This effect might be achieveable by other
nononcogenic genes or even through ex-
ogenous growth factors. (2) The genera-
tion of iPS cells without c-Myc virus repre-
sents an important advancement toward
less-tumorigenic iPS cells. So far, 18 out
of the 36 four-factor iPS cell chimeras
that have been produced in our laboratory
died within the first 8 months of cancer
(M.W. and R.J., unpublished data), and
tumors have been regularly observed in
mice derived after germline transmission
(Okita et al., 2007). Long-term studies
will, therefore, be required to evaluate
whether reprogramming without c-Myc
reduces the risk of cancer, but it is likelyCell Stem Cell 2, January 2008 ª2008 Elsevier Inc. 11
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Shown are the results of clone 3F-N2. Neomycin-resistant clones homogenously expressed Nanog (A) and SSEA1 (B) and had strong alkaline phosphatase ac-
tivity (C). (A0) and (B0) represent the corresponding DAPI stainings.When injected into SCIDmice, the iPS cells formed teratomas containing bone tissue (red arrow
in [D]), neuroectoderm (black arrowhead in [D]), and cuboidal epithelia (E). After infection with a GFP-expressing lentivirus (FUW-GFP) (Lois et al., 2002) and in-
jection into diploid blastocysts, the three-factor iPS cells generated live newborn (F and F0) and adult chimeric mice (G). Scale bar in (B0 ) represents 100 mm for (A)
and (B) and 200 mm for (C). Scale bar in (D) represents 200 mm for (D) and 50 mm for (E).that mice derived from iPS cells that do
not carry a c-Myc provirus will develop
fewer tumors if not remain completely tu-
mor free. However, we cannot rule out
that an endogenous Myc gene was acti-
vated by retroviral insertional mutagene-
sis. While difficult to formally disprove,
a number of considerations argue against
this possibility. We have failed to find rear-
rangements of the endogenous c-Myc
locus by Southern blot analysis in all
nine tested three-factor iPS cell lines
(data not shown). Also, if retrovirus-
mediated c-Myc activation was important
for reprogramming, it would explain the
lower overall efficiency of reprogramming
but not the substantial delay of iPS cell
appearance in the absence of virus-medi-
ated c-myc transduction. Rather, our
results suggest that c-Myc transduction
increases the fraction of reprogrammed
cells and accelerates the reprogramming
process possibly by increasing the speed
of stochastic events that lead to the12 Cell Stem Cell 2, January 2008 ª2008 Elsformation of iPS cells (Meissner et al.,
2007).
Materials and Methods
Mice, cell lines, retroviral vectors, cell cul-
ture, immunostainings, and blastocyst in-
jections were previously described in de-
tail (Wernig et al., 2007).
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